<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6"><gtr:id>0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6</gtr:id><gtr:name>Hebrew University of Jerusalem</gtr:name><gtr:address><gtr:line1>Mt Scopus</gtr:line1><gtr:line4>Jerusalem</gtr:line4><gtr:line5>91905</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2A2C4471-6207-410F-AF5E-A4074808D65B"><gtr:id>2A2C4471-6207-410F-AF5E-A4074808D65B</gtr:id><gtr:name>Miltenyi Biotec GmBH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B93051EA-16E5-42A4-A3BE-8541E933EF7D"><gtr:id>B93051EA-16E5-42A4-A3BE-8541E933EF7D</gtr:id><gtr:name>Ben Gurion University of the Negev</gtr:name><gtr:address><gtr:line1>Ben Gurion University of the Negev</gtr:line1><gtr:line2>PO Box 653</gtr:line2><gtr:line3>84105</gtr:line3><gtr:line4>Beer-Sheva</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>School of Biological Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6"><gtr:id>0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6</gtr:id><gtr:name>Hebrew University of Jerusalem</gtr:name><gtr:address><gtr:line1>Mt Scopus</gtr:line1><gtr:line4>Jerusalem</gtr:line4><gtr:line5>91905</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2A2C4471-6207-410F-AF5E-A4074808D65B"><gtr:id>2A2C4471-6207-410F-AF5E-A4074808D65B</gtr:id><gtr:name>Miltenyi Biotec GmBH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B93051EA-16E5-42A4-A3BE-8541E933EF7D"><gtr:id>B93051EA-16E5-42A4-A3BE-8541E933EF7D</gtr:id><gtr:name>Ben Gurion University of the Negev</gtr:name><gtr:address><gtr:line1>Ben Gurion University of the Negev</gtr:line1><gtr:line2>PO Box 653</gtr:line2><gtr:line3>84105</gtr:line3><gtr:line4>Beer-Sheva</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AF91AE49-D2AF-4701-BD30-997A9675BAB9"><gtr:id>AF91AE49-D2AF-4701-BD30-997A9675BAB9</gtr:id><gtr:firstName>Timothy Edward</gtr:firstName><gtr:surname>Hardingham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/72265151-89A7-450E-A15F-F2080AD38054"><gtr:id>72265151-89A7-450E-A15F-F2080AD38054</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Kimber</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F785B423-CFB6-4A4C-B8BA-802DC65552DB"><gtr:id>F785B423-CFB6-4A4C-B8BA-802DC65552DB</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Brison</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL004992%2F1"><gtr:id>DAF0BE2E-1697-41E9-88ED-E01806AEE6E6</gtr:id><gtr:title>Chondrocytes from Clinical Grade Embryonic Stem Cells</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L004992/1</gtr:grantReference><gtr:abstractText>Osteoarthritis is a debilitating condition of joints affecting 25% of adults over 65 yrs (WHO estimate). It causes pain, disability and loss of independence, which results in a poor quality of life. In the EU it is ranked 12th for disease burden with 35-40 million sufferers and this is set to rise with increased ageing of the population. Current clinical treatment is limited to pain relief with nothing able to delay or reverse the condition. Irreversibly damaged joints are eventually replaced by synthetic prostheses, which are successful in older patients (&amp;gt;65), but less so in younger patients whose life expectancy is much greater than that of the prosthesis and revision surgery is less successful. There is therefore a large unmet clinical need for improved treatment for OA. Current strategies include cartilage repair (ACI) using the patient's own chondrocytes, harvested from intact areas of tissue. However, the outcome of ACI is little better than non-cellular orthopaedic treatments and it requires 2 operations and damage to otherwise intact tissue. Patients' stem cells are also being tested from bone marrow, but this also requires 2 operations and patient specific cell culture. To overcome the problem of the variable quality of the patients' own cells and the need for 2 operations, we have developed a protocol to generate chondrocytes from human embryonic stem cells (hESCs). The protocol is entirely serum free, chemically defined and yields up to 97% chondrogenic cells. We now need to adapt this procedure to deliver cells suitable for clinical applications. This requires the use of entirely validated clinical grade reagents, scale up to generate larger numbers of cells and methods to store and deliver cells to the clinic. We will validate this protocol with a new generation of very high quality (clinical grade) stem cell lines derived in Manchester and by other Centres across the UK. The advantage of using hESCs is that they can be expanded to produce enough chondrogenic cells to treat large numbers of patients, making such a therapy cost-effective on the NHS. Follow-up tests in vivo will grade lines for success in repairing focal defects in rat knee joints (already shown for research grade cells) to allow us to assess the quality of in vivo cartilage repair and assess any incidence of tumour formation, or other adverse effects. The plan will show if hESC derived chondrocytes can be produced, delivered and are able to complete hyaline cartilage repair. This award will allow us to establish the means and methods to move forward towards phase 1 clinical trials for patients with focal cartilage defects.</gtr:abstractText><gtr:technicalSummary>Current clinical treatment for osteoarthritis, which affects 25% of adults over 65 yrs (WHO estimate), is limited to pain relief and there is no treatment able to delay or reverse the condition. Irreversibly damaged joints are eventually replaced by synthetic prostheses, which are successful in older patients (&amp;gt;65), but less so in younger patients whose life expectancy is much greater than that of the prosthesis and revision surgery is less successful. There is therefore a large unmet clinical need for improved treatment for OA. To address this need we developed a protocol to differentiate pluripotent stem cells to chondrogenic cells at high efficiency and these cells which can repair cartilage defects in a rodent model. The protocol is entirely serum free, chemically defined and yields up to 97% chondrogenic cells. We will now adapt this procedure to deliver cells suitable for clinical applications, meeting current Good Manufacturing Practice (cGMP ) standards. We will employ strategies leading to greater cell expansion; apply our refined protocol to a range of clinical grade hESC lines derived in Manchester and in other Centres, evaluating lines for chondrogenic bias. The differentiated cells will be tested for their ability to repair a surgical cartilage defect, without evidence of adverse effects including the generation of ectopic growths or tumours in i) a rat defect model and ii) in a pilot study for a larger animal, the sheep. We will develop and test methods for the clinical delivery and storage of the cells using fibrin gels, evaluating viability and shelf life.</gtr:technicalSummary><gtr:potentialImpactText>We intend this preclinical application to lead to the development of phase 1 clinical trials which will provide direct patient benefit and new treatment options for joint trauma and OA sufferers. This will be for focal cartilage defects in the first instance but with potential for repairing larger OA lesions as clinical experience is gained. We will generate hESC-chondrocytes which are suitable for use for patients as part of planning for subsequent clinical trials with our clinical collaborators (Sanjay Anand and David Johnson, Stockport NHS Trust). The development of our protocol will lead the way in providing proof of principle for cell therapies from pluripotent cells for both academics and clinicians. 

Academics will benefit from our development and refinement of reproducible protocols, increased understanding of cartilage development and homeostasis. Our work will provide in vitro and in vivo model system for understanding responses to inflammatory mediators and extracellular matrix targeted drugs. We will interact with members of the UK Regenerative Medicine platform hubs to share our findings of translation and learn from their experiences, exploiting their findings where possible e.g. in imaging and safety.

NHS: Our work will start to open up a pathway for this and similar therapies to be incorporated into NHS treatments. 
Regulators: Our engagement with the regulators will also help to inform regulatory procedures for cell therapy especially those from pluripotent cells.

Patient Groups and General public: Firstly our projected therapy will provide a cell based treatment and so make a real impact on the quality of life to patients with sports injury and osteoarthritis. Secondly, we will engage with patient groups and member of the public to inform them of our activities and learn further from them regarding patient perception of need, in a continuation of our previous public engagement activities. 

Biopharma: We will interact further with companies interested in cell therapy or who may wish to use our findings to generate new in vitro models for testing drugs active in modulating extracellular matrix repair. We will seek advice from biopharma and the Catapult with a view to their active engagement as we move towards the clinic.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-06-08</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-06-09</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>622461</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Miltenyi Biotec GmBH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Miltenyi</gtr:description><gtr:id>0A593947-D0EF-41CC-826B-6F1FBE1A3F39</gtr:id><gtr:impact>Too early</gtr:impact><gtr:partnerContribution>Cell sorting expertise and kits/antibodies/plates for FACs based cell sorting for enrichment of chondroprogenitors</gtr:partnerContribution><gtr:piContribution>We have submitted a large grant application to Arthritis Research Uk with Miltenyi. If successful they will contribute in kind support with cell sorting and GMP translationof our protocol for clinical therapy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Hebrew University of Jerusalem</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>Understanding regulation of chondrogenesis by Sirt1</gtr:description><gtr:id>327739E9-E3D8-490F-8ABB-C509C19B6574</gtr:id><gtr:impact>ARUK grant obtained</gtr:impact><gtr:partnerContribution>Training in CHIP technology for Post doc in host lab. Expertise in CHIP,CHIP-CHIP, epigentic modifificaiton and analysis,cartilage biology Exchange of reagents and knowledge.</gtr:partnerContribution><gtr:piContribution>Collaboration to understand epigenetic regulation of hESC chondrogenesis through regulation by histone deacetylases</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ben Gurion University</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>GAG analysis 1</gtr:description><gtr:id>7282627E-250F-4125-9709-A6E5BB700588</gtr:id><gtr:impact>initiating only</gtr:impact><gtr:partnerContribution>Initiating</gtr:partnerContribution><gtr:piContribution>We generate the cellular model , they may analyse GAGS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center (Erasmus MC)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Erasmus MC Rotterdam</gtr:description><gtr:id>B274076A-93B5-4240-B5F7-B81B41185539</gtr:id><gtr:impact>Shared research skills and model exchange; collaboration on research programme</gtr:impact><gtr:partnerContribution>Collaboration including a month's research time at host institute</gtr:partnerContribution><gtr:piContribution>Collaboration including a month's research time at host institute, Consultancy for iPSC generation and differentiation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited lecture to EU Student Parliament debate on embryo research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>21675FA7-D26F-488A-A2CC-EB44BCF355CA</gtr:id><gtr:impact>Invited lecture to EU Student parliament debate on human embryo research including embryonic stem cell derivation, in Salford, UK</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Women in Science Becoming the Best</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>77CDBC76-BB61-42F5-BB25-C254B1A6C01B</gtr:id><gtr:impact>Dissemaination of information advice and support for women's role and leadership in scince</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Membership of HFEA's Scientific and Clinical Advances Advisory Committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FCE5ACF7-EC5A-446C-B013-D417DD81B2C6</gtr:id><gtr:impact>Membership of HFEA's Scientific and Clinical Advances Advisory Committee</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEM Cell Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0F56938D-E7E4-4696-8526-1B4DD127D64E</gtr:id><gtr:impact>Talk triggered questions and interest

Students suggested they would like to apply for bio/biomed in Manchester</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Membership of HFEA's Information for Quality Programme</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3A25AD47-08D0-43A5-B356-AFAC13D5B619</gtr:id><gtr:impact>Membership of HFEA's Information for Quality Programme</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CMFT Xmas lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>77F23640-FCAF-4BB1-A528-10F3ED753AF2</gtr:id><gtr:impact>Xmas Royal Society-style lecture for Central Manchester NHS Foundation Trust &amp;quot;The Stem Cell Revolution&amp;quot;.

School visit requests</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio 4 interview with Mark Porter</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>11838842-B2CF-4216-ACFC-FE2805552458</gtr:id><gtr:impact>Sue Kimber interviewed on Radio 4 Case Notes programme re stem cell therapies

Raised public awareness, led to doubled patient and GP interest in NWESCC</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Media Centre press conference</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F82B301-D498-41A0-A9C6-573FEE00BC12</gtr:id><gtr:impact>Press conference organised by SMC to discuss press release concerning submission of clinical grade embryonic stem cell lines to the UK Stem Cell Bank

Interest from media, followup stories. Followup contacts from industry resulting directly from press release.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New Scientist Article on ART child health</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DBD17C1B-B5FE-45BA-9EF0-2CB209B0A252</gtr:id><gtr:impact>Interview for article in New Scientist on research into ART child health</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cell Therapy Catapult</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3C4534F8-F5C6-4E29-8823-3FC59341C95A</gtr:id><gtr:impact>We were informing the Catapult of our activities towerds Cell therapy for Cartilage. They were advising us on most optimal way forward.

Beter informed on both sides</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancashire Humanists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D8AF1EA5-55DF-4FA8-A1B6-66F18E57D3F0</gtr:id><gtr:impact>70 people attenced a public lecture on stem cell biology

Requests for other talks to Humanist groups.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio 4 interview re 'Promising' stem cell trials for blindness</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>816C68AE-428D-4705-BBE3-8D857FB0A549</gtr:id><gtr:impact>Daniel Brison interviewed and commented on news story re stem cell therapies

Raising public awareness</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Guardian newspaper article on ART child health</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>40E0679D-4933-4F69-A032-3B82188837B4</gtr:id><gtr:impact>Guardian newspaper article on ART child health</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HFEA Information for Quality programme</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F8CA3688-5B2B-4A26-8FB6-2CA074B3FA2B</gtr:id><gtr:impact>acting as advisor to Human Fertilisation and Embryology Authority Information for quality programme which aims to improve regulatory oversight of the field including stem cell derivation, and improve information to patients and for delivery of clinical IVF services.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing policy towards patenting of discoveries using hESC lines</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>9E441464-24CF-4F59-BC2F-5E1658320005</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of HFEA's Scientific and Clinical Advances committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A16BBF15-D57C-46DF-B131-BBC35D76C294</gtr:id><gtr:impact>Advising the HFEA on changes in regulation on embryology and embryonic stem cell biology</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Clinical human Embryonic Stem Cell Forum</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E3489F0C-7210-4CA5-9635-12DD3EE46071</gtr:id><gtr:impact>Standardisation of requirements for clinical grade embryonic stem cell lines. Prof Brison is vice-chair of this group</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ESHRE working group on the impact of embryo culture medium on long term health</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>0BC7E908-EC6D-4904-B4F4-087B84BCE7D6</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of TERMIS Scientific Advisory Board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E11E139C-EB6A-4BD4-B0C8-F14012E52263</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Stem Cells for Safer Medicine Panel Member</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>39188A29-301B-427A-9D0A-85A433B00FE2</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Setting standards for procurement of embryonic stem cells at clinical grade</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41A35BBA-CC02-4FB1-98A7-59E5018DCB61</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cochrane guideline on embryo culture temperature</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>48816B52-3D38-45DE-ABA7-3811AE8BCEA0</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Human ESCs were labelled with GFP using lentiviral vector.</gtr:description><gtr:id>991A31F9-9A72-46DB-BB3C-46E8BCAF3A18</gtr:id><gtr:impact>These cells could be used for studies requiring tracing cell migration or destination.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GFP labelled human ESCs</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>immortalisation of GMP grade fibroblasts under clean room conditions</gtr:description><gtr:id>6BE7A4E8-EA45-4F8E-93BF-E640144DF983</gtr:id><gtr:impact>Research advance and help to UKSCB</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>immortalisation of GMP grade fibroblasts under clean room conditions</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of method to repair osteochondral defect in a large animal</gtr:description><gtr:id>B76579B6-E2DF-452C-9232-FBD480EC74D6</gtr:id><gtr:impact>No impact yet but paper will be written shortly</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Repair of cartilage defect in sheep</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5ED9217D-B1F4-41FC-9B8C-7496BD1E8204"><gtr:id>5ED9217D-B1F4-41FC-9B8C-7496BD1E8204</gtr:id><gtr:title>Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation.</gtr:title><gtr:parentPublicationTitle>Stem cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e24510e4994add39b1b7fe2204a470d"><gtr:id>0e24510e4994add39b1b7fe2204a470d</gtr:id><gtr:otherNames>Vitillo L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-6711</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B787FF8-EFAC-4F66-8DAE-54135F53C77C"><gtr:id>0B787FF8-EFAC-4F66-8DAE-54135F53C77C</gtr:id><gtr:title>LEF1-mediated MMP13 gene expression is repressed by SIRT1 in human chondrocytes</gtr:title><gtr:parentPublicationTitle>Arthritis and Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a2afdd779983ac8044a2caa047fac571"><gtr:id>a2afdd779983ac8044a2caa047fac571</gtr:id><gtr:otherNames> ELAYYAN J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E650292-99BF-4F0E-AE4F-102BD2EA8C6D"><gtr:id>2E650292-99BF-4F0E-AE4F-102BD2EA8C6D</gtr:id><gtr:title>Current evidence for ART practice: the Cochrane of Cochranes on optimising outcomes.</gtr:title><gtr:parentPublicationTitle>Evidence-based medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6745dc9d496018514a97679b9b676727"><gtr:id>6745dc9d496018514a97679b9b676727</gtr:id><gtr:otherNames>Harper JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1356-5524</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L004992/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>